Teva Pharmaceutical Industries (TEVA)
(Delayed Data from NYSE)
$17.51 USD
-0.25 (-1.41%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $17.51 0.00 (0.00%) 7:52 PM ET
3-Hold of 5 3
A Value B Growth A Momentum A VGM
Company Summary
Headquartered in Tel Aviv, Israel, Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets both branded and generic drugs (includes biosimilars and over-the-counter (“OTC”) products), as well as active pharmaceutical ingredients (APIs) in North America, Europe, Latin America, India, and Israel. Teva’s generic product portfolio includes tablets, capsules, liquids, ointments, creams, transdermal patches, injectables, and inhalants. Teva plans to separate its API unit into a standalone business unit, whose divestment is expected to be completed in the first half of 2025.
The company’s branded ...
Company Summary
Headquartered in Tel Aviv, Israel, Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets both branded and generic drugs (includes biosimilars and over-the-counter (“OTC”) products), as well as active pharmaceutical ingredients (APIs) in North America, Europe, Latin America, India, and Israel. Teva’s generic product portfolio includes tablets, capsules, liquids, ointments, creams, transdermal patches, injectables, and inhalants. Teva plans to separate its API unit into a standalone business unit, whose divestment is expected to be completed in the first half of 2025.
The company’s branded products include Copaxone (multiple sclerosis - MS), Austedo (chorea associated with Huntington’s disease and tardive dyskinesia), Ajovy (preventive treatment of migraine) and legacy respiratory products like ProAir and Qvar.
Teva operates through three segments, United States (previously North America), Europe and International Markets, each of which includes generics, specialty and OTC products. In 2023, North America accounted for 51.3% of Teva’s sales while Europe and International Markets accounted for 30.5% and 12.4% of total sales, respectively.
In early August 2016, Teva acquired Allergan’s generics business – Actavis Generics – for $33.43 billion in cash and about 100 million Teva shares. The company also acquired Allergan’s Anda Inc., the fourth largest distributor of generic pharmaceuticals in the United States in October 2016. In May 2015, Teva acquired Auspex Pharmaceuticals, which strengthened its core CNS franchise. The December 2008 Barr acquisition boosted Teva’s product portfolio significantly. The acquisition enhanced Teva’s leadership position in the United States and allowed it to expand its presence in Europe. In October 2011, Teva acquired Cephalon for $6.8 billion. Teva has strengthened its position in Europe through its acquisition of Germany’s second-largest generics producer, ratiopharm.
In July 2018, Teva terminated its partnership with P&G - PGT Healthcare, which marketed OTC medicines.
Teva’s 2023 total revenues declined 6.2% to $15.8 billion.
General Information
Teva Pharmaceutical Industries Ltd
124 DVORA HANEVI'a STREET
TEL AVIV, L3 6944020
Phone: 972-3914-8213
Fax: 972-3923-4050
Email: tevair@tevapharm.com
Industry | Medical - Generic Drugs |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 6/30/2024 |
Exp Earnings Date | 11/13/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | 0.65 |
Current Year EPS Consensus Estimate | 2.43 |
Estimated Long-Term EPS Growth Rate | 6.20 |
Exp Earnings Date | 11/13/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 17.76 |
52 Week High | 19.08 |
52 Week Low | 8.06 |
Beta | 0.88 |
20 Day Moving Average | 6,940,525.50 |
Target Price Consensus | 19.50 |
4 Week | -3.43 |
12 Week | 9.23 |
YTD | 70.11 |
4 Week | -5.84 |
12 Week | 4.81 |
YTD | 42.01 |
Shares Outstanding (millions) | 1,132.91 |
Market Capitalization (millions) | 20,120.46 |
Short Ratio | NA |
Last Split Date | 7/1/2004 |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | 0.00 |
Change in Payout Ratio | 0.00 |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | 7.32 |
Trailing 12 Months | 6.60 |
PEG Ratio | 1.19 |
vs. Previous Year | 7.41% |
vs. Previous Quarter | 26.09% |
vs. Previous Year | 7.37% |
vs. Previous Quarter | 9.03% |
Price/Book | 3.07 |
Price/Cash Flow | 5.05 |
Price / Sales | 1.24 |
6/30/24 | 39.66 |
3/31/24 | 37.33 |
12/31/23 | 34.90 |
6/30/24 | 6.95 |
3/31/24 | 6.73 |
12/31/23 | 6.48 |
6/30/24 | 0.89 |
3/31/24 | 0.89 |
12/31/23 | 1.02 |
6/30/24 | 0.59 |
3/31/24 | 0.61 |
12/31/23 | 0.69 |
6/30/24 | 18.10 |
3/31/24 | 18.01 |
12/31/23 | 17.59 |
6/30/24 | -2.73 |
3/31/24 | -2.88 |
12/31/23 | -3.33 |
6/30/24 | -0.87 |
3/31/24 | -5.12 |
12/31/23 | -3.94 |
6/30/24 | 5.79 |
3/31/24 | 6.66 |
12/31/23 | 7.25 |
6/30/24 | 2.06 |
3/31/24 | 2.03 |
12/31/23 | 2.01 |
6/30/24 | 2.52 |
3/31/24 | 2.20 |
12/31/23 | 2.23 |
6/30/24 | 71.60 |
3/31/24 | 68.74 |
12/31/23 | 69.09 |